Nuciferine modulates the gut microbiota and prevents obesity in high-fat diet-fed rats

다국어 초록 (Multilingual Abstract)

Gut microbiota dysbiosis has a significant role in the pathogenesis of metabolic diseases, including obesity. Nuciferine (NUC) is a main bioactive component in the lotus leaf that has been used as food in China since ancient times. Here, we examined whether the anti-obesity effects of NUC are related to modulations in the gut microbiota. Using an obese rat model fed a HFD for 8 weeks, we show that NUC supplementation of HFD rats prevents weight gain, reduces fat accumulation, and ameliorates lipid metabolic disorders. Furthermore, 16S rRNA gene sequencing of the fecal microbiota suggested that NUC changed the diversity and composition of the gut microbiota in HFD-fed rats. In particular, NUC decreased the ratio of the phyla Firmicutes/Bacteroidetes, the relative abundance of the LPS-producing genus Desulfovibrio and bacteria involved in lipid metabolism, whereas it increased the relative abundance of SCFA-producing bacteria in HFD-fed rats. Predicted functional analysis of microbial communities showed that NUC modified genes involved in LPS biosynthesis and lipid metabolism. In addition, serum metabolomics analysis revealed that NUC effectively improved HFD-induced disorders of endogenous metabolism, especially lipid metabolism. Notably, NUC promoted SCFA production and enhanced intestinal integrity, leading to lower blood endotoxemia to reduce inflammation in HFD-fed rats. Together, the anti-obesity effects of NUC may be related to modulations in the composition and potential function of gut microbiota, improvement in intestinal barrier integrity and prevention of chronic low-grade inflammation. This research may provide support for the application of NUC in the prevention and treatment of obesity.

참고문헌 (Reference)

1 Togo, A. H., "“Anaerotruncus massiliensis,” a new species identified from human stool from an obese patient after bariatric surgery" 14 : 56-57, 2016

2 Cui, H., "Untargeted metabolomic analysis of the effects and mechanism of nuciferine treatment on rats with nonalcoholic fatty liver disease" 11 : 858-, 2020

3 Xu, J., "Understanding the molecular mechanisms of the interplay between herbal medicines and gut microbiota" 37 : 1140-1185, 2017

4 Komaroff, A. L., "The microbiome and risk for obesity and diabetes" 317 : 355-356, 2017

5 Backhed, F., "The gut microbiota as an environmental factor that regulates fat storage" 101 : 15718-15723, 2004

6 Zhang, X., "Structural changes of gut microbiota during berberinemediated prevention of obesity and insulin resistance in high-fat diet-fed rats" 7 : e42529-, 2012

7 Meikle, P. J., "Sphingolipids and phospholipids in insulin resistance and related metabolic disorders" 13 : 79-91, 2017

8 Xiong, Y., "Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41" 101 : 1045-1050, 2004

9 Canfora, E. E., "Short-chain fatty acids in control of body weight and insulin sensitivity" 11 : 577-591, 2015

10 Lu, Y., "Short chain fatty acids prevent high-fat-diet-induced obesity in mice by regulating G protein-coupled receptors and gut microbiota" 6 : 37589-, 2016

11 Bouter, K. E., "Role of the gut microbiome in the pathogenesis of obesity and obesity-related metabolic dysfunction" 152 : 1671-1678, 2017

12 Org, E., "Relationships between gut microbiota, plasma metabolites, and metabolic syndrome traits in the METSIM cohort" 18 : 70-, 2017

13 Lackey, D. E., "Regulation of metabolism by the innate immune system" 12 : 15-28, 2016

14 Suzuki, T., "Regulation of intestinal epithelial permeability by tight junctions" 70 : 631-659, 2013

15 Caporaso, J. G., "QIIME allows analysis of high-throughput community sequencing data" 7 : 335-336, 2010

16 Langille, M. G., "Predictive functional profiling of microbial communities using 16s rRNA marker gene sequences" 31 : 814-821, 2013

17 Liu, M., "Potent effects of dioscin against obesity in mice" 5 : 7973-, 2015

18 Flint, H. J., "Polysaccharide utilization by gut bacteria : Potential for new insights from genomic analysis" 6 : 121-131, 2008

19 Liu, J., "Oral hydroxysafflor yellow a reduces obesity in mice by modulating the gut microbiota and serum metabolism" 134 : 40-50, 2018

20 Feldman, G. J., "Occludin : Structure, function and regulation" 57 : 883-917, 2005

21 Ley, R. E., "Obesity alters gut microbial ecology" 102 : 11070-11075, 2005

22 Guo, F., "Nuciferine prevents hepatic steatosis and injury induced by a high-fat diet in hamsters" 8 : e63770-, 2013

23 Zhang, C., "Nuciferine ameliorates hepatic steatosis in high-fat diet/streptozocin-induced diabetic mice through a PPARα/PGC1α pathway" 175 : 4218-4228, 2018

24 Rodriguez-Nunez, I., "Nod2 and Nod2-regulated microbiota protect BALB/c mice from diet-induced obesity and metabolic dysfunction" 7 : 548-, 2017

25 Wang, Q., "Naïve Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy" 73 : 5261-5267, 2007

26 De Vadder, F., "Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits" 156 : 84-96, 2014

27 Ploger, S., "Microbial butyrate and its role for barrier function in the gastrointestinal tract" 1258 : 52-59, 2012

28 Cani, P. D., "Metabolic endotoxemia initiates obesity and insulin resistance" 56 : 1761-1772, 2007

29 Backhed, F., "Mechanisms underlying the resistance to diet-induced obesity in germ-free mice" 104 : 979-984, 2007

30 Rauschert, S., "Lipidomics reveals associations of phospholipids with obesity and insulin resistance in young adults" 101 : 871-879, 2016

31 Saad, M. J., "Linking gut microbiota and inflammation to obesity and insulin resistance" 31 : 283-293, 2016

32 Juskiewicz, J., "Lactulose-induced diarrhoea in rats : Effects on caecal development and activities of microbial enzymes" 133 : 411-417, 2002

33 Clavel, T., "Isolation of bacteria from the ileal mucosa of TNFdeltaARE mice and description of Enterorhabdus mucosicola gen" 59 : 1805-1812, 2009

34 Clavel, T., "Intestinal microbiota in metabolic diseases : from bacterial community structure and functions to species of pathophysiological relevance" 5 : 544-551, 2014

35 Kameyama, K., "Intestinal colonization by a Lachnospiraceae bacterium contributes to the development of diabetes in obese mice" 29 : 427-430, 2014

36 Kaakoush, N. O., "Insights into the role of Erysipelotrichaceae in the human host" 5 : 84-, 2015

37 Daniel, H., "High-fat diet alters gut microbiota physiology in mice" 8 : 295-308, 2014

38 Kim, K. A., "High fat diet-induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway" 7 : e47713-, 2012

39 Afshin, A., "Health effects of overweight and obesity in 195 countries" 377 : 1496-1497, 2017

40 Wang, Y. C., "Health and economic burden of the projected obesity trends in the USA and the UK" 378 : 815-825, 2011

41 Ridaura, V. K., "Gut microbiota from twins discordant for obesity modulate metabolism in mice" 341 : 1241214-, 2013

42 Tremaroli, V., "Functional interactions between the gut microbiota and host metabolism" 489 : 242-249, 2012

43 Abdallah Ismail, N., "Frequency of Firmicutes and Bacteroidetes in gut microbiota in obese and normal weight Egyptian children and adults" 7 : 501-507, 2011

44 Peng, L., "Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier" 61 : 37-41, 2007

45 De Minicis, S., "Dysbiosis contributes to fibrogenesis in the course of chronic liver injury in mice" 59 : 1738-1749, 2014

46 Bervoets, L., "Differences in gut microbiota composition between obese and lean children : a cross-sectional study" 5 : 10-, 2013

47 Martinez, I., "Diet-induced alterations of host cholesterol metabolism are likely to affect the gut microbiota composition in hamsters" 79 : 516-524, 2013

48 Cani, P. D., "Changes in gut microbiota control metabolic endotoxemiainduced inflammation in high-fat diet-induced obesity and diabetes in mice" 57 : 1470-1481, 2008

49 Sakamoto, M., "Butyricimonas synergistica gen. nov., sp. nov. and Butyricimonas virosa sp. nov., butyric acid-producing bacteria in the family ‘Porphyromonadaceae’ isolated from rat faeces" 59 : 1748-1753, 2009

50 Puertollano, E., "Biological significance of short-chain fatty acid metabolism by the intestinal microbiome" 17 : 139-144, 2014

51 Bluher, M., "Are there still healthy obese patients? Curr" 19 : 341-346, 2012

52 Rankin, W., "Anti-obesity drugs" 26 : 536-543, 2015

53 Parker, B. L., "An integrative systems genetic analysis of mammalian lipid metabolism" 567 : 187-193, 2019

54 Zietak, M., "Altered microbiota contributes to reduced diet-induced obesity upon cold exposure" 23 : 1216-1223, 2016

55 Hong, Y. H., "Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43" 146 : 5092-5099, 2005

56 Gu, S., "A sensitive liquid chromatography-tandem mass spectrometry method for pharmacokinetics and tissue distribution of nuciferine in rats" 961 : 20-28, 2014

57 Stenman, L. K., "A novel mechanism for gut barrier dysfunction by dietary fat: Epithelial disruption by hydrophobic bile acids" 304 : G227-G234, 2013

58 Xiao, S., "A gut microbiota-targeted dietary intervention for amelioration of chronic inflammation underlying metabolic syndrome" 87 : 357-367, 2014

59 Sharma, B. R., "A comprehensive review on chemical profiling of Nelumbo Nucifera: Potential for drug development" 31 : 3-26, 2017

60 Cremonini, E., "(-)-Epicatechin protects the intestinal barrier from high fat diet-induced permeabilization : Implications for steatosis and insulin resistance" 14 : 588-599, 2018